Researchers sought to determine whether combination ibrutinib and venetoclax would improve outcomes in patients with CLL compared with chlorambucil plus obinutuzumab.
Ibrutinib does not improve overall survival in patients with treatment-naïve chronic lymphocytic leukemia at high risk of progression, a phase 3 trial suggests.
Researchers investigated whether adding venetoclax to ibrutinib and obinutuzumab would improve survival and allow for discontinuation of treatment in older patients with CLL.
Researchers sought to better discriminate true MRD positivity for risk stratification in chronic lymphocytic leukemia and acute lymphoblastic leukemia in children.
Researchers sought to determine whether patients with CLL/SLL would be able to maintain fixed dosing schedule of venetoclax-based regimens in their treatments.
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Chronic lymphocytic leukemia (CLL) is a chronic incurable mature B-cell neoplasm that often does not require immediate treatment; however, when patients experience symptoms, such as anemia, cytopenias, or bulky lymphadenopathy, therapy is required. During a presentation at the 2022 Oncology Nurse Advisor Summit, Laura J. Zitella, MS, RN, ACNP-BC, AOCN, an associate clinical professor at…
Researchers sought to determine whether a third dose of the BNT162b2 mRNA vaccine against COVID-19 may induce an antibody response in patients with CLL or SLL.
Researchers sought to determine whether different doses of ponatinib would have benefit for patients with resistant chronic-phase chronic myeloid leukemia.
Researchers sought to determine whether MRD would improve after fixed-duration treatment with venetoclax and obinutuzumab therapy in patients with CLL.